Download PDF
Semin Respir Crit Care Med 2016; 37(02): 214-229
DOI: 10.1055/s-0036-1572558
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bacterial Respiratory Infections Complicating Human Immunodeficiency Virus

Charles Feldman
1   Division of Pulmonology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
,
Ronald Anderson
2   Institute for Cellular and Molecular Medicine, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa
› Author Affiliations
Further Information

Publication History

Publication Date:
14 March 2016 (online)

    Permissions and Reprints

Abstract

Opportunistic bacterial and fungal infections of the lower respiratory tract, most commonly those caused by Streptococcus pneumoniae (the pneumococcus), Mycobacterium tuberculosis, and Pneumocystis jirovecii, remain the major causes of mortality in those infected with human immunodeficiency virus (HIV). Bacterial respiratory pathogens most prevalent in those infected with HIV, other than M. tuberculosis, represent the primary focus of the current review with particular emphasis on the pneumococcus, the leading cause of mortality due to HIV infection in the developed world. Additional themes include (1) risk factors; (2) the predisposing effects of HIV-mediated suppression on pulmonary host defenses, possibly intensified by smoking; (3) clinical and laboratory diagnosis, encompassing assessment of disease severity and outcome; and (4) antibiotic therapy. The final section addresses current recommendations with respect to pneumococcal immunization in the context of HIV infection, including an overview of the rationale underpinning the current “prime-boost” immunization strategy based on sequential administration of pneumococcal conjugate vaccine 13 and pneumococcal polysaccharide vaccine 23.

Keywords

community-acquired pneumonia - host defenses - outcome - pneumococcal immunization - pneumococcus - risk factors - severity of illness - treatment
 

  • References

  • 1 Mayaud C, Parrot A, Cadranel J. Pyogenic bacterial lower respiratory tract infection in human immunodeficiency virus-infected patients. Eur Respir J Suppl 2002; 36 (Suppl. 36) 28s-39s
    PubMedGoogle Scholar
  • 2 Benito N, Moreno A, Miro JM, Torres A. Pulmonary infections in HIV-infected patients: an update in the 21st century. Eur Respir J 2012; 39 (3) 730-745
    CrossrefPubMedGoogle Scholar
  • 3 Segal LN, Methé BA, Nolan A , et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc Am Thorac Soc 2011; 8 (3) 282-287
    CrossrefPubMedGoogle Scholar
  • 4 Brown J, Lipman M. Community-acquired pneumonia in HIV-infected individuals. Curr Infect Dis Rep 2014; 16 (3) 397
    CrossrefPubMedGoogle Scholar
  • 5 Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med 2013; 34 (2) 205-216
    CrossrefPubMedGoogle Scholar
  • 6 Feldman C, Anderson R. Respiratory infections in specific populations: HIV patients. In: Blasi F, Dimopoulos G, eds. Textbook of Respiratory and Critical Care Infections. New Delhi, India: Jaypee Brothers Medical Publishers; 2015: 139-158
    Google Scholar
  • 7 Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4 (7) 445-455
    CrossrefPubMedGoogle Scholar
  • 8 Boschini A, Smacchia C, Di Fine M , et al. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996; 23 (1) 107-113
    CrossrefPubMedGoogle Scholar
  • 9 Kohli R, Lo Y, Homel P , et al; HER Study Group. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43 (1) 90-98
    CrossrefPubMedGoogle Scholar
  • 10 Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120 (6) 1888-1893
    CrossrefPubMedGoogle Scholar
  • 11 Sullivan JH, Moore RD, Keruly JC, Chaisson RE. Effect of antiretroviral therapy on the incidence of bacterial pneumonia in patients with advanced HIV infection. Am J Respir Crit Care Med 2000; 162 (1) 64-67
    CrossrefPubMedGoogle Scholar
  • 12 Hirschtick RE, Glassroth J, Jordan MC , et al; Pulmonary Complications of HIV Infection Study Group. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333 (13) 845-851
    CrossrefPubMedGoogle Scholar
  • 13 Tumbarello M, Tacconelli E, de Gaetano K , et al. Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (1) 39-45
    CrossrefPubMedGoogle Scholar
  • 14 Madeddu G, Porqueddu EM, Cambosu F , et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36 (3) 231-236
    CrossrefPubMedGoogle Scholar
  • 15 Madeddu G, Laura Fiori M, Stella Mura M. Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med 2010; 16 (3) 201-207
    PubMedGoogle Scholar
  • 16 Mussini C, Galli L, Lepri AC , et al; ICONA Foundation Study Group. Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort. J Acquir Immune Defic Syndr 2013; 63 (3) 339-345
    CrossrefPubMedGoogle Scholar
  • 17 Penner J, Meier AS, Mwachari C , et al. Risk factors for pneumonia in urban-dwelling HIV-infected women: a case-control study in Nairobi, Kenya. J Acquir Immune Defic Syndr 2003; 32 (2) 223-228
    CrossrefPubMedGoogle Scholar
  • 18 Navin TR, Rimland D, Lennox JL , et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000; 181 (1) 158-164
    CrossrefPubMedGoogle Scholar
  • 19 Bjerk SM, Baker JV, Emery S , et al; INSIGHT SMART Study Group. Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS ONE 2013; 8 (2) e56249
    CrossrefPubMedGoogle Scholar
  • 20 Twigg III HL, Knox KS. Impact of antiretroviral therapy on lung immunology and inflammation. Clin Chest Med 2013; 34 (2) 155-164
    CrossrefPubMedGoogle Scholar
  • 21 Huson MA, Grobusch MP, van der Poll T. The effect of HIV infection on the host response to bacterial sepsis. Lancet Infect Dis 2015; 15 (1) 95-108
    CrossrefPubMedGoogle Scholar
  • 22 Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J 2015; 46 (6) 1781-1795
    CrossrefPubMedGoogle Scholar
  • 23 Perreau M, Savoye AL, De Crignis E , et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210 (1) 143-156
    CrossrefPubMedGoogle Scholar
  • 24 Jambo KC, Banda DH, Kankwatira AM , et al. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. Mucosal Immunol 2014; 7 (5) 1116-1126
    CrossrefPubMedGoogle Scholar
  • 25 Gordon SB, Jagoe RT, Jarman ER , et al. The alveolar microenvironment of patients infected with human immunodeficiency virus does not modify alveolar macrophage interactions with Streptococcus pneumoniae . Clin Vaccine Immunol 2013; 20 (6) 882-891
    CrossrefPubMedGoogle Scholar
  • 26 Malley R. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Mol Med (Berl) 2010; 88 (2) 135-142
    CrossrefPubMedGoogle Scholar
  • 27 Crothers K, Griffith TA, McGinnis KA , et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med 2005; 20 (12) 1142-1145
    CrossrefPubMedGoogle Scholar
  • 28 Feldman JG, Minkoff H, Schneider MF , et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women's interagency HIV study. Am J Public Health 2006; 96 (6) 1060-1065
    CrossrefPubMedGoogle Scholar
  • 29 Gordin FM, Roediger MP, Girard P-M , et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med 2008; 178 (6) 630-636
    CrossrefPubMedGoogle Scholar
  • 30 Petrosillo N, Cicalini S. Smoking and HIV: time for a change?. BMC Med 2013; 11: 16
    CrossrefPubMedGoogle Scholar
  • 31 Helleberg M, Afzal S, Kronborg G , et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013; 56 (5) 727-734
    CrossrefPubMedGoogle Scholar
  • 32 Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. J Infect 2013; 67 (3) 169-184
    CrossrefPubMedGoogle Scholar
  • 33 Sapkota AR, Berger S, Vogel TM. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect 2010; 118 (3) 351-356
    PubMedGoogle Scholar
  • 34 Brook I, Gober AE. Recovery of potential pathogens and interfering bacteria in the nasopharynx of smokers and nonsmokers. Chest 2005; 127 (6) 2072-2075
    CrossrefPubMedGoogle Scholar
  • 35 Voss M, Wonnenberg B, Honecker A , et al. Cigarette smoke-promoted acquisition of bacterial pathogens in the upper respiratory tract leads to enhanced inflammation in mice. Respir Res 2015; 16 (1) 41
    CrossrefPubMedGoogle Scholar
  • 36 Kulkarni R, Antala S, Wang A , et al. Cigarette smoke increases Staphylococcus aureus biofilm formation via oxidative stress. Infect Immun 2012; 80 (11) 3804-3811
    CrossrefPubMedGoogle Scholar
  • 37 Mutepe ND, Cockeran R, Steel HC , et al. Effects of cigarette smoke condensate on pneumococcal biofilm formation and pneumolysin. Eur Respir J 2013; 41 (2) 392-395
    CrossrefPubMedGoogle Scholar
  • 38 Hutcherson JA, Scott DA, Bagaitkar J. Scratching the surface - tobacco-induced bacterial biofilms. Tob Induc Dis 2015; 13 (1) 1
    CrossrefPubMedGoogle Scholar
  • 39 Kearley J, Silver JS, Sanden C , et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015; 42 (3) 566-579
    CrossrefPubMedGoogle Scholar
  • 40 Bourdonnay E, Zasłona Z, Penke LR , et al. Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signaling. J Exp Med 2015; 212 (5) 729-742
    CrossrefPubMedGoogle Scholar
  • 41 Grigg J, Walters H, Sohal SS , et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. Thorax 2012; 67 (10) 908-913
    CrossrefPubMedGoogle Scholar
  • 42 Schamberger AC, Mise N, Jia J , et al. Cigarette smoke-induced disruption of bronchial epithelial tight junctions is prevented by transforming growth factor-β. Am J Respir Cell Mol Biol 2014; 50 (6) 1040-1052
    CrossrefPubMedGoogle Scholar
  • 43 Lozupone C, Cota-Gomez A, Palmer BE , et al; Lung HIV Microbiome Project. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med 2013; 187 (10) 1110-1117
    CrossrefPubMedGoogle Scholar
  • 44 Cui L, Lucht L, Tipton L , et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am J Respir Crit Care Med 2015; 191 (8) 932-942
    CrossrefPubMedGoogle Scholar
  • 45 Morris A, Beck JM, Schloss PD , et al; Lung HIV Microbiome Project. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med 2013; 187 (10) 1067-1075
    CrossrefPubMedGoogle Scholar
  • 46 Sopena N, Pedro-Botet ML, Sabrià M, García-Parés D, Reynaga E, García-Nuñez M. Comparative study of community-acquired pneumonia caused by Streptococcus pneumoniae, Legionella pneumophila or Chlamydia pneumoniae . Scand J Infect Dis 2004; 36 (5) 330-334
    CrossrefPubMedGoogle Scholar
  • 47 Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect 2012; 42 (10) 517-524
    CrossrefPubMedGoogle Scholar
  • 48 Kyaw MH, Rose Jr CE, Fry AM , et al; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192 (3) 377-386
    CrossrefPubMedGoogle Scholar
  • 49 Lynch III JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009; 30 (2) 189-209
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Mufson MA, Hao JB, Stanek RJ, Norton NB. Clinical features of patients with recurrent invasive Streptococcus pneumoniae disease. Am J Med Sci 2012; 343 (4) 303-309
    CrossrefPubMedGoogle Scholar
  • 51 Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE ; Adult and Adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001; 32 (5) 794-800
    CrossrefPubMedGoogle Scholar
  • 52 Perelló R, Miró O, Marcos MA , et al. Predicting bacteremic pneumonia in HIV-1-infected patients consulting the ED. Am J Emerg Med 2010; 28 (4) 454-459
    CrossrefPubMedGoogle Scholar
  • 53 Munier AL, de Lastours V, Porcher R, Donay JL, Pons JL, Molina JM. Risk factors for invasive pneumococcal disease in HIV-infected adults in France in the highly active antiretroviral therapy era. Int J STD AIDS 2014; 25 (14) 1022-1028
    CrossrefPubMedGoogle Scholar
  • 54 Jover F, Cuadrado JM, Andreu L , et al. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia. Eur J Intern Med 2008; 19 (1) 15-21
    CrossrefPubMedGoogle Scholar
  • 55 Yin Z, Rice BD, Waight P , et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS 2012; 26 (1) 87-94
    CrossrefPubMedGoogle Scholar
  • 56 Madeddu G, Fois AG, Pirina P, Mura MS. Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV noninfected patients. Curr Opin Pulm Med 2009; 15 (3) 236-242
    CrossrefPubMedGoogle Scholar
  • 57 Feldman C, Klugman KP, Yu VL , et al; International Pneumococcal Study Group. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect 2007; 55 (2) 125-135
    CrossrefPubMedGoogle Scholar
  • 58 Schleicher GK, Feldman C. Dual infection with Streptococcus pneumoniae and Mycobacterium tuberculosis in HIV-seropositive patients with community acquired pneumonia. Int J Tuberc Lung Dis 2003; 7 (12) 1207-1208
    PubMedGoogle Scholar
  • 59 Sanz JC, Cercenado E, Marín M , et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect 2011; 17 (7) 1094-1098
    CrossrefPubMedGoogle Scholar
  • 60 Isea-Peña MC, Sanz-Moreno JC, Esteban J, Fernández-Roblas R, Fernández-Guerrero ML. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae . Infection 2013; 41 (5) 935-939
    CrossrefPubMedGoogle Scholar
  • 61 Allen SH, Brennan-Benson P, Nelson M , et al. Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era. Postgrad Med J 2003; 79 (938) 691-694
    PubMedGoogle Scholar
  • 62 Jordano Q, Falcó V, Almirante B , et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38 (11) 1623-1628
    CrossrefPubMedGoogle Scholar
  • 63 Heffernan RT, Barrett NL, Gallagher KM , et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005; 191 (12) 2038-2045
    CrossrefPubMedGoogle Scholar
  • 64 Saindou M, Chidiac C, Miailhes P , et al. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods. HIV Med 2008; 9 (4) 203-207
    CrossrefPubMedGoogle Scholar
  • 65 Siemieniuk RAC, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis 2011; 11: 314
    CrossrefPubMedGoogle Scholar
  • 66 Nunes MC, von Gottberg A, de Gouveia L , et al. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS ONE 2011; 6 (11) e27929
    CrossrefPubMedGoogle Scholar
  • 67 Falcó V, Burgos J, Pahissa A. The spectrum of invasive pneumococcal disease in adults in the XXI century. Clin Pulm Med 2013; 20 (5) 214-220
    CrossrefPubMedGoogle Scholar
  • 68 Schlamm HT, Yancovitz SR. Haemophilus influenzae pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med 1989; 86 (1) 11-14
    CrossrefPubMedGoogle Scholar
  • 69 Moreno S, Martinez R, Barros C, Gonzalez-Lahoz J, Garcia-Delgado E, Bouza E. Latent Haemophilus influenzae pneumonia in patients infected with HIV. AIDS 1991; 5 (8) 967-970
    CrossrefPubMedGoogle Scholar
  • 70 Casadevall A, Dobroszycki J, Small C, Pirofski LA. Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. Am J Med 1992; 92 (6) 587-590
    CrossrefPubMedGoogle Scholar
  • 71 Rich JD, Sax PE, Kazanjian PH. Bacteremic H. influenzae type b infections and HIV. Am J Med 1993; 95 (1) 118-119
    PubMedGoogle Scholar
  • 72 Muñoz P, Miranda ME, Llancaqueo A, Peláez T, Rodríguez-Créixems M, Bouza E. Haemophilus species bacteremia in adults. The importance of the human immunodeficiency virus epidemic. Arch Intern Med 1997; 157 (16) 1869-1873
    CrossrefPubMedGoogle Scholar
  • 73 Cordero E, Pachón J, Rivero A , et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Clin Infect Dis 2000; 30 (3) 461-465
    CrossrefPubMedGoogle Scholar
  • 74 Levine SJ, White DA, Fels AO. The incidence and significance of Staphylococcus aureus in respiratory cultures from patients infected with the human immunodeficiency virus. Am Rev Respir Dis 1990; 141 (1) 89-93
    CrossrefPubMedGoogle Scholar
  • 75 Tumbarello M, Tacconelli E, Lucia MB, Cauda R, Ortona L. Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. Respir Med 1996; 90 (9) 531-537
    CrossrefPubMedGoogle Scholar
  • 76 Gil Suay V, Cordero PJ, Martínez E , et al. Parapneumonic effusions secondary to community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients. Eur Respir J 1995; 8 (11) 1934-1939
    CrossrefPubMedGoogle Scholar
  • 77 Lobo LJ, Reed KD, Wunderink RG. Expanded clinical presentation of community-acquired methicillin-resistant Staphylococcus aureus pneumonia. Chest 2010; 138 (1) 130-136
    CrossrefPubMedGoogle Scholar
  • 78 Daneshvar C, Smith NC, Waghorn DJ, Luzzi GA, Wathen CG. Community-acquired pneumonia due to Panton-Valentine leukocidin-producing Staphylococcus aureus in an HIV-2-infected patient. Int J STD AIDS 2011; 22 (10) 610-612
    CrossrefPubMedGoogle Scholar
  • 79 Tarp B, Jensen JS, Ostergaard L, Andersen PL. Search for agents causing atypical pneumonia in HIV-positive patients by inhibitor-controlled PCR assays. Eur Respir J 1999; 13 (1) 175-179
    CrossrefPubMedGoogle Scholar
  • 80 Sandkovsky U, Sandkovsky G, Suh J, Smith B, Sharp V, Polsky B. Legionella pneumonia and HIV: case reports and review of the literature. AIDS Patient Care STDS 2008; 22 (6) 473-481
    CrossrefPubMedGoogle Scholar
  • 81 Pedro-Botet ML, Sabrià M, Sopena N , et al. Legionnaires disease and HIV infection. Chest 2003; 124 (2) 543-547
    CrossrefPubMedGoogle Scholar
  • 82 Robbins NM, Kumar A, Blair BM. Legionella pneumophila infection presenting as headache, confusion and dysarthria in a human immunodeficiency virus-1 (HIV-1) positive patient: case report. BMC Infect Dis 2012; 12: 225
    CrossrefPubMedGoogle Scholar
  • 83 Comandini UV, Maggi P, Santopadre P, Monno R, Angarano G, Vullo V. Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997; 16 (10) 720-726
    CrossrefPubMedGoogle Scholar
  • 84 Tositti G, Rassu M, Fabris P , et al. Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile. HIV Med 2005; 6 (1) 27-32
    CrossrefPubMedGoogle Scholar
  • 85 Shankar EM, Kumarasamy N, Vignesh R , et al. Epidemiological studies on pulmonary pathogens in HIV-positive and -negative subjects with or without community-acquired pneumonia with special emphasis on Mycoplasma pneumoniae . Jpn J Infect Dis 2007; 60 (6) 337-341
    PubMedGoogle Scholar
  • 86 Ali NJ, Kessel D, Miller RF. Bronchopulmonary infection with Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. Genitourin Med 1995; 71 (2) 73-77
    PubMedGoogle Scholar
  • 87 Meynard JL, Barbut F, Guiguet M , et al. Pseudomonas aeruginosa infection in human immunodeficiency virus infected patients. J Infect 1999; 38 (3) 176-181
    CrossrefPubMedGoogle Scholar
  • 88 Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117 (4) 1017-1022
    CrossrefPubMedGoogle Scholar
  • 89 Manfredi R, Nanetti A, Ferri M, Chiodo F. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey. Eur J Epidemiol 2000; 16 (2) 111-118
    CrossrefPubMedGoogle Scholar
  • 90 Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171 (11) 1209-1223
    CrossrefPubMedGoogle Scholar
  • 91 Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 2010; 15 (7) 1037-1056
    CrossrefPubMedGoogle Scholar
  • 92 Fujitani S, Sun HY, Yu VL, Weingarten JA. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139 (4) 909-919
    CrossrefPubMedGoogle Scholar
  • 93 Topino S, Galati V, Grilli E, Petrosillo N. Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS 2010; 24 (4) 211-222
    CrossrefPubMedGoogle Scholar
  • 94 Manfredi R, Nanetti A, Valentini R, Chiodo F. Moraxella catarrhalis pneumonia during HIV disease. J Chemother 2000; 12 (5) 406-411
    CrossrefPubMedGoogle Scholar
  • 95 Smith MD, Derrington P, Evans R , et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003; 41 (7) 2810-2813
    CrossrefPubMedGoogle Scholar
  • 96 Jørgensen CS, Uldum SA, Sørensen JF, Skovsted IC, Otte S, Elverdal PL. Evaluation of a new lateral flow test for detection of Streptococcus pneumoniae and Legionella pneumophila urinary antigen. J Microbiol Methods 2015; 116: 33-36
    CrossrefPubMedGoogle Scholar
  • 97 Sheppard CL, Harrison TG, Smith MD, George RC. Development of a sensitive, multiplexed immunoassay using xMAP beads for detection of serotype-specific streptococcus pneumoniae antigen in urine samples. J Med Microbiol 2011; 60 (Pt 1) 49-55
    CrossrefPubMedGoogle Scholar
  • 98 Pride MW, Huijts SM, Wu K , et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012; 19 (8) 1131-1141
    CrossrefPubMedGoogle Scholar
  • 99 Elberse K, van Mens S, Cremers AJ , et al. Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infect Dis 2015; 15: 56
    CrossrefPubMedGoogle Scholar
  • 100 Slotved HC, Kaltoft M, Skovsted IC, Kerrn MB, Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). J Clin Microbiol 2004; 42 (6) 2518-2522
    CrossrefPubMedGoogle Scholar
  • 101 Kuch A, Gołȩbiewska A, Waśko I , et al. Usefulness of Pneumotest-latex for direct serotyping of Streptococcus pneumoniae isolates in clinical samples. J Clin Microbiol 2014; 52 (7) 2647-2649
    CrossrefPubMedGoogle Scholar
  • 102 Carvalho MdaG, Tondella ML, McCaustland K , et al. Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol 2007; 45 (8) 2460-2466
    CrossrefPubMedGoogle Scholar
  • 103 Werno AM, Anderson TP, Murdoch DR. Association between pneumococcal load and disease severity in adults with pneumonia. J Med Microbiol 2012; 61 (Pt 8) 1129-1135
    CrossrefPubMedGoogle Scholar
  • 104 Strålin K, Herrmann B, Abdeldaim G, Olcén P, Holmberg H, Mölling P. Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets lytA and Spn9802 for quantitative PCR for rapid detection of pneumococcal pneumonia. J Clin Microbiol 2014; 52 (1) 83-89
    CrossrefPubMedGoogle Scholar
  • 105 Bogaerts P, Hamels S, de Mendonca R , et al. Analytical validation of a novel high multiplexing real-time PCR array for the identification of key pathogens causative of bacterial ventilator-associated pneumonia and their associated resistance genes. J Antimicrob Chemother 2013; 68 (2) 340-347
    CrossrefPubMedGoogle Scholar
  • 106 Jamal W, Al Roomi E, AbdulAziz LR, Rotimi VO. Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia. J Clin Microbiol 2014; 52 (7) 2487-2492
    CrossrefPubMedGoogle Scholar
  • 107 Gadsby NJ, McHugh MP, Russell CD , et al. Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections. Clin Microbiol Infect 2015; 21 (8) 788.e1-788.e13
    CrossrefPubMedGoogle Scholar
  • 108 Jain S, Self WH, Wunderink RG , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373 (5) 415-427
    CrossrefPubMedGoogle Scholar
  • 109 Chamie G, Luetkemeyer A, Walusimbi-Nanteza M , et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis 2010; 14 (10) 1295-1302
    PubMedGoogle Scholar
  • 110 Piatek AS, Van Cleeff M, Alexander H , et al. GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract 2013; 1 (1) 18-23
    PubMedGoogle Scholar
  • 111 Theron G, Peter J, van Zyl-Smit R , et al. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting. Am J Respir Crit Care Med 2011; 184 (1) 132-140
    CrossrefPubMedGoogle Scholar
  • 112 Hanrahan CF, Theron G, Bassett J , et al. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med 2014; 189 (11) 1426-1434
    CrossrefPubMedGoogle Scholar
  • 113 Florin TA, Ambroggio L. Biomarkers for community-acquired pneumonia in the emergency department. Curr Infect Dis Rep 2014; 16 (12) 451
    CrossrefPubMedGoogle Scholar
  • 114 Kolditz M, Ewig S, Höffken G. Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013; 41 (4) 974-984
    CrossrefPubMedGoogle Scholar
  • 115 Mandell LA, Wunderink RG, Anzueto A , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    CrossrefPubMedGoogle Scholar
  • 116 Mello CF, Negra MD. Impact of macrolide therapy on mortality of HIV-infected patients with community-acquired pneumonia in a tertiary teaching hospital. Braz J Infect Dis 2011; 15 (3) 262-267
    CrossrefPubMedGoogle Scholar
  • 117 Baddour LM, Yu VL, Klugman KP , et al; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170 (4) 440-444
    CrossrefPubMedGoogle Scholar
  • 118 Curran A, Falcó V, Crespo M , et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med 2008; 9 (8) 609-615
    CrossrefPubMedGoogle Scholar
  • 119 Cordero E, Pachón J, Rivero A , et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Am J Respir Crit Care Med 2000; 162 (6) 2063-2068
    CrossrefPubMedGoogle Scholar
  • 120 Chew KW, Yen IH, Li JZ, Winston LG. Predictors of pneumonia severity in HIV-infected adults admitted to an urban public hospital. AIDS Patient Care STDS 2011; 25 (5) 273-277
    CrossrefPubMedGoogle Scholar
  • 121 Barakat LA, Juthani-Mehta M, Allore H , et al. Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia. HIV Med 2015; 16 (7) 421-430
    CrossrefPubMedGoogle Scholar
  • 122 Yone EW, Balkissou AD, Kengne AP, Kuaban C. Influence of HIV infection on the clinical presentation and outcome of adults with acute community-acquired pneumonia in Yaounde, Cameroon: a retrospective hospital-based study. BMC Pulm Med 2012; 12: 46
    CrossrefPubMedGoogle Scholar
  • 123 Christensen D, Feldman C, Rossi P , et al; Community-Acquired Pneumonia Organization Investigators. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis 2005; 41 (4) 554-556
    CrossrefPubMedGoogle Scholar
  • 124 Malinis M, Myers J, Bordon J , et al. Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. Int J Infect Dis 2010; 14 (1) e22-e27
    PubMedGoogle Scholar
  • 125 Bordon J, Kapoor R, Martinez C , et al. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. Int J Infect Dis 2011; 15 (12) e822-e827
    CrossrefPubMedGoogle Scholar
  • 126 Feldman C, Glatthaar M, Morar R , et al. Bacteremic pneumococcal pneumonia in HIV-seropositive and HIV-seronegative adults. Chest 1999; 116 (1) 107-114
    CrossrefPubMedGoogle Scholar
  • 127 Morris AM, Huang L, Bacchetti P , et al; The Pulmonary Complications of HIV Infection Study Group. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. Am J Respir Crit Care Med 2000; 162 (2, Pt 1) 612-616
    CrossrefPubMedGoogle Scholar
  • 128 Osmond DH, Chin DP, Glassroth J , et al; Pulmonary Complications of HIV Study Group. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Clin Infect Dis 1999; 29 (3) 536-543
    CrossrefPubMedGoogle Scholar
  • 129 Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Infect 2014; 69 (4) 309-325
    CrossrefPubMedGoogle Scholar
  • 130 Musher DM. Pneumococcal vaccination in adults. UpToDate; April 2015, Available at: www.uptodate.com
    PubMedGoogle Scholar
  • 131 WHO . Pneumococcal polysaccharide vaccine. WHO position paper; March 2008 , Available at: http://www.who.int/immunization/sage/1_PPV23_draft_March_3_clean.pdf
    PubMed
  • 132 Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis 2015; 60 (10) 1472-1480
    PubMedGoogle Scholar
  • 133 Russell KL, Baker CI, Hansen C , et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine 2015; 33 (9) 1182-1187
    CrossrefPubMedGoogle Scholar
  • 134 Peñaranda M, Falco V, Payeras A , et al. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis 2007; 45 (7) e82-e87
    CrossrefPubMedGoogle Scholar
  • 135 Rodriguez-Barradas MC, Goulet J, Brown S , et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46 (7) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 136 Imaz A, Falcó V, Peñaranda M , et al. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease. HIV Med 2009; 10 (6) 356-363
    CrossrefPubMedGoogle Scholar
  • 137 French N, Nakiyingi J, Carpenter LM , et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355 (9221) 2106-2111
    CrossrefPubMedGoogle Scholar
  • 138 Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59 (34) 1102-1106
    PubMedGoogle Scholar
  • 139 Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61 (40) 816-819
    PubMedGoogle Scholar
  • 140 Moore MR, Link-Gelles R, Schaffner W , et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15 (3) 301-309
    CrossrefPubMedGoogle Scholar
  • 141 Lepoutre A, Varon E, Georges S , et al; Microbiologists of Epibac; ORP Networks. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 33 (2) 359-366
    CrossrefPubMedGoogle Scholar
  • 142 Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015; 15 (5) 535-543
    CrossrefPubMedGoogle Scholar
  • 143 Chacon-Cruz E, Rivas-Landeros RM, Volker-Soberanes ML. Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital. Ther Adv Vaccines 2014; 2 (6) 155-158
    PubMedGoogle Scholar
  • 144 Bonten MJ, Huijts SM, Bolkenbaas M , et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372 (12) 1114-1125
    CrossrefPubMedGoogle Scholar
  • 145 Tomczyk S, Bennett NM, Stoecker C , et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63 (37) 822-825
    PubMedGoogle Scholar
  • 146 Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N ; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349 (14) 1341-1348
    CrossrefPubMedGoogle Scholar
  • 147 French N, Gordon SB, Mwalukomo T , et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010; 362 (9) 812-822
    CrossrefPubMedGoogle Scholar
  • 148 Chan CY, Molrine DC, George S , et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173 (1) 256-258
    CrossrefPubMedGoogle Scholar
  • 149 Lesprit P, Pédrono G, Molina JM , et al; ANRS 114-Pneumovac Study Group. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21 (18) 2425-2434
    CrossrefPubMedGoogle Scholar
  • 150 Kumar D, Chen MH, Wong G , et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47 (7) 885-892
    CrossrefPubMedGoogle Scholar
  • 151 Miernyk KM, Butler JC, Bulkow LR , et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin Infect Dis 2009; 49 (2) 241-248
    CrossrefPubMedGoogle Scholar
  • 152 Jackson LA, Gurtman A, van Cleeff M , et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31 (35) 3577-3584
    CrossrefPubMedGoogle Scholar
  • 153 Jackson LA, Gurtman A, van Cleeff M , et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31 (35) 3594-3602
    CrossrefPubMedGoogle Scholar
  • 154 Greenberg RN, Gurtman A, Frenck RW , et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014; 32 (20) 2364-2374
    CrossrefPubMedGoogle Scholar
  • 155 Iyer AS, Leggat DJ, Ohtola JA , et al. Response to pneumococcal polysaccharide vaccination in HIV-positive individuals on long term highly active antiretroviral therapy. J AIDS Clin Res 2015; 6 (2) 421
    PubMedGoogle Scholar
  • 156 Hibberd PL. Immunizations in HIV-infected patients. UpToDate; May 2015; Available at: www.uptodate.com
    PubMedGoogle Scholar
  • 157 Leggat DJ, Iyer AS, Ohtola JA , et al. Response to pneumococcal polysaccharide vaccination in newly diagnosed HIV-positive individuals. J AIDS Clin Res 2015; 6 (2) 419
    PubMedGoogle Scholar
  • 158 Rodriguez-Barradas MC, Serpa JA, Munjal I , et al. Quantitative and qualitative antibody responses to immunization with the pneumococcal polysaccharide vaccine in HIV-infected patients after initiation of antiretroviral treatment: results from a randomized clinical trial. J Infect Dis 2015; 211 (11) 1703-1711
    CrossrefPubMedGoogle Scholar
  • 159 Engsig FN, Zangerle R, Katsarou O , et al; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014; 58 (9) 1312-1321
    CrossrefPubMedGoogle Scholar
  • 160 Zoufaly A, Cozzi-Lepri A, Reekie J , et al; EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS ONE 2014; 9 (1) e87160
    CrossrefPubMedGoogle Scholar
  • 161 Braitstein P, Brinkhof MW, Dabis F , et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367 (9513) 817-824
    CrossrefPubMedGoogle Scholar
  • 162 Keiser O, Orrell C, Egger M , et al; Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA). Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5 (7) e148
    CrossrefPubMedGoogle Scholar
  • 163 Kantsø B, Green N, Goldblatt D, Benfield T. Antibody response is more likely to pneumococcal proteins than to polysaccharide after HIV-associated invasive pneumococcal disease. J Infect Dis 2015; 212 (7) 1093-1099
    CrossrefPubMedGoogle Scholar
  • 164 Mdodo R, Frazier EL, Dube SR , et al. Cigarette smoking prevalence among adults with HIV compared with the general population in the United States. Ann Intern Med 2015; 162 (5) 335-344
    CrossrefPubMedGoogle Scholar
  • 165 McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19 (3) 571-582
    CrossrefPubMedGoogle Scholar
  • 166 Remschmidt C, Wichmann O, Harder T. Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine 2014; 32 (43) 5585-5592
    CrossrefPubMedGoogle Scholar
  • 167 Cohen C, Moyes J, Tempia S , et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009-2013. PLoS ONE 2015; 10 (3) e0118884
    CrossrefPubMedGoogle Scholar